RX 549
Latest Information Update: 16 Jul 2002
Price :
$50 *
At a glance
- Originator Chugai Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 23 Feb 2000 Preclinical development for Cancer in Japan (Unknown route)
- 18 Feb 2000 No-Development-Reported for Cancer in Japan (Unknown route)
- 21 Apr 1997 New profile